Literature DB >> 793499

Failure of customary treatment in chronic active liver disease: causes and management.

S W Schalm, H V Ammon, W H Summerskill.   

Abstract

Among 134 patients with chronic active liver disease, selected by identical clinical, biochemical and morphologic criteria, assigned to standard treatment programs and followed at regular intervals, 21 of 105 failed treatment with standard regimens containing steroids. Treatment failure was more common in patients whose serum contained hepatitis B surface antigen, those with more severe liver disease as judged by liver function tests (prothrombin time) and hepatic morphology (subacute hepatitis or cirrhosis). Early diagnosis of treatment failure, based on changes in liver function tests rather than on clinical features of deterioration, coupled with the immediate administration of higher doses of prednisone with or without higher doses of azathioprine, resulted in disappearance of clinical and biochemical features of disease activity in the majority of patients. These results were greatly superior to those earlier reported by us from patients chosen by identical criteria but treated by conventional measures. However, when endogenous encephalopathy developed the outlook was grave, regardless of previous or subsequent therapy. We recommend that patients at risk for failing conventional treatment be identified early, followed carefully with serial liver function tests, and be treated promptly with higher doses of medication when deterioration occurs.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 793499

Source DB:  PubMed          Journal:  Ann Clin Res        ISSN: 0003-4762


  21 in total

Review 1.  Advances in the current treatment of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-04-03       Impact factor: 3.199

2.  Prognostic determinants in chronic hepatitis B infection-a reevaluation.

Authors:  J L Boyer
Journal:  West J Med       Date:  1978-04

3.  Different types of smooth muscle antibodies in chronic active hepatitis and primary biliary cirrhosis: their diagnostic and prognostic significance.

Authors:  P Kurki; A Miettinen; E Linder; P Pikkarainen; M Vuoristo; M P Salaspuro
Journal:  Gut       Date:  1980-10       Impact factor: 23.059

Review 4.  Difficult treatment decisions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  World J Gastroenterol       Date:  2010-02-28       Impact factor: 5.742

Review 5.  Acute and acute severe (fulminant) autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-10-23       Impact factor: 3.199

6.  A Case of Autoimmune Hepatitis Treated with Rituximab.

Authors:  E Barth; J Clawson
Journal:  Case Rep Gastroenterol       Date:  2010-11-23

7.  Liver transplantation in adults: Choosing the appropriate timing.

Authors:  Maria Siciliano; Lucia Parlati; Federica Maldarelli; Massimo Rossi; Stefano Ginanni Corradini
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-08-06

Review 8.  Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment.

Authors:  Albert J Czaja; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2009-05-21       Impact factor: 5.742

9.  Comparative serum prednisone and prednisolone concentrations following administration to patients with chronic active liver disease.

Authors:  M Uribe; W H Summerskill; V L Go
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

Review 10.  Drug therapy in the management of type 1 autoimmune hepatitis.

Authors:  A J Czaja
Journal:  Drugs       Date:  1999-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.